IE 11 is not supported. For an optimal experience visit our site on another browser.
  • UP NEXT

    Missing nature, man creates company to connect people outdoors

    04:35
  • Prince William resumes duties after Kate's cancer announcement

    02:24
  • Uber releases list of most unique items left behind in cars

    00:37
  • NBA issues lifetime ban against Jontay Porter for betting on games

    00:19
  • Columbia University president testifies over campus antisemitism

    02:17
  • Bryan Kohberger's lawyers say he has an alibi for night of murders

    03:11
  • Second round of severe storms sweep through Midwest

    03:23
  • DOJ settlement for victims of Larry Nassar likely around $100M

    00:38
  • Whistleblower testifies Boeing is 'putting out defective airplanes’

    02:29
  • Vultures nursed back to health after getting drunk in bar's dumpster

    00:37
  • Arizona GOP blocks another attempt to repeal 1864 abortion ban

    02:02
  • Speaker Johnson moves ahead on foreign aid amid ousting threat

    02:10
  • Emergency responders scramble during 911 outages in 4 states

    02:12
  • Hannah Waddingham on why Jason Sudeikis is ‘very special to me’

    02:05
  • Nostalgia on display: How this company is reviving the split-flap board

    04:41
  • Paris Olympics by the numbers: Preps, previews, athletes to watch

    04:19
  • Escaped circus elephant runs loose through Montana streets

    02:23
  • How Paris is preparing to host its first Olympics in 100 years

    06:18
  • Trillions of cicadas to appear in first double emergence in 200 years

    03:01
  • US to impose new sanctions on Tehran in wake of attack on Israel

    02:31

Pfizer executive: ‘We’re confident’ about our vaccine being safe and effective for kids

04:44

Dr. Bill Gruber, Pfizer’s senior vice president of vaccine clinical research and development as well as a pediatrician, joins TODAY to talk about new data released from Pfizer showing its vaccine to be safe and effective for kids between 5 and 11. He says, “We intend to submit the data [to the FDA] by the end of the month.” He adds, “We’re hopeful and expectant that the FDA will approve the vaccine based on the data we have.” He also discusses an FDA panel’s recommendations about a third booster shot for adults.